Cangene (FRA:YGE) Debt-to-Asset : 0.00 (As of Oct. 2013)

View and export this data going back to . Start your Free Trial

What is Cangene Debt-to-Asset?

Cangene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2013 was €0.00 Mil. Cangene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2013 was €0.00 Mil. Cangene's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Oct. 2013 was €208.85 Mil. Cangene's debt to asset for the quarter that ended in Oct. 2013 was 0.00.

Cangene Debt-to-Asset Historical Data

The historical data trend for Cangene's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Debt-to-Asset Chart

Cangene Annual Data

Trend

Jul04

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

Debt-to-Asset

Get a 7-Day Free Trial

Cangene Quarterly Data
	Jan09	Apr09	Jul09	Oct09	Jan10	Apr10	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cangene's Debt-to-Asset

For the Biotechnology subindustry, Cangene's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cangene's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cangene's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cangene's Debt-to-Asset falls into.

Cangene Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cangene's Debt-to-Asset for the fiscal year that ended in Jul. 2013 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	218.9
	=	0.00

Cangene's Debt-to-Asset for the quarter that ended in Oct. 2013 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	208.847
	=	0.00

Cangene (FRA:YGE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cangene Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cangene's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cangene (FRA:YGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cangene.com

Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines